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Abstract We assessed the relations between MPA, free
MPA (fMPA) and MPA glucuronide (MPAG) pharma-
cokinetics and the clinical condition of renal transplant
recipients treated with EC-MPS and tacrolimus (Tac) in the
first post-transplant year. In 18 adult patients blood samples
were collected up to 12 h after EC-MPS oral administra-
tion. EC-MPS metabolites’ plasma concentrations were
determined using validated HPLC methods. All patients
reached MPA area under the time–concentration curve
(AUC0–12) above 30 lg h/mL. Most of the MPA, fMPA
and all MPAG concentrations correlated significantly with
respective AUC0–12 values. Some fMPA and all MPAG
pharmacokinetic parameters correlated negatively with
creatinine clearance and positively with creatinine con-
centration, whereas no such correlation was observed for
MPA. Lower hemoglobin concentrations were observed in
patients with higher MPA or fMPA C0. The significant
correlations between MPA C3 as well as MPA C4 and MPA
AUC0–4 and MPA AUC0–12 may be of importance in fur-
ther studies including larger number of patients in regard to
establishing LSS. In patients treated with EC-MPS and
Tac, monitoring MPA C0 may be important, as too high
MPA C0 may contribute to anemia onset. In EC-MPS
treated patients, MPAG concentration is related to renal
function as MPAG pharmacokinetics were higher in
patients with renal impairment.
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1 Introduction
The enteric-coated formulation of mycophenolate sodium
(EC-MPS, Myfortic, Novartis Pharma AG, Basel,
Switzerland), used in the prophylaxis of organ rejection,
was developed to reduce the incidence of adverse gas-
trointestinal effects of its active compound, mycophenolic
acid (MPA) (Budde et al. 2010; Sa´nchez Fructuoso et al.
2012). EC-MPS has similar safety profile and adverse
gastrointestinal effects incidence (Salvadori et al. 2004;
Budde et al. 2007b) to mycophenolate mofetil (MMF,
CellCept, Roche AG, Basel, Switzerland). EC-MPS is still
most often administrated basing on fixed doses, without
monitoring MPA concentrations although MPA is charac-
terized by high protein binding (97–99 %) (Chen et al.
2010) as well as high intra- and interpatient variability of its
pharmacokinetics and pharmacodynamics (Budde et al.
2010; Sa´nchez Fructuoso et al. 2012). The EC-MPS therapy
is most often controlled only by assessing patient’s clinical
condition, although there are some data indicating the
efficacy-exposure relationship. In some studies, the correla-
tion between small drug concentration and the risk of acute
rejection or between high drug concentration and adverse
effects intensity (Budde et al. 2007b, 2010; Sa´nchez Fruc-
tuoso et al. 2012; Durlik and Rowin´ski 2012) was observed.
The best method for effective and safe immunosuppressive
therapy is monitoring the active metabolite plasma con-
centration (Durlik and Rowin´ski 2012), especially as MPA
pharmacokinetics may be influenced by co-administration
of other immunosuppressant agents, albumin concentration
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and renal function as well as the pharmacokinetics may vary
depending on the type of organ transplanted (Budde et al.
2010).
Pharmacokinetic parameters of MPA and its inactive
metabolite, MPA glucuronide (MPAG), depend on the kind
of calcineurin inhibitor [cyclosporine (CsA) or tacrolimus
(Tac)] co-administrated. CsA may affect the enterohepatic
recirculation of MPAG, leading to MPA AUC decrease,
whereas Tac influence on the recirculation is probably
lower; therefore, MPA exposure is higher in EC-MPS and
Tac-treated patients (Kaplan et al. 2005). According to our
knowledge, the influence of CsA on EC-MPS pharma-
cokinetics is widely described in the literature (Budde et al.
2007b; Sanford and Keating 2008; Budde et al. 2010;
Capone et al. 2011; Stracke et al. 2012). Although EC-MPS
is also frequently co-administered with Tac, more data
need to be evaluated for safe and effective therapy (Budde
et al. 2007a; Sa´nchez Fructuoso et al. 2012; Ju et al. 2012;
Lee et al. 2012; Li et al. 2013).
The main difficulty is that the determination of the area
under the plasma concentration–time curve from 0 to 12 h
(AUC0–12), which describes best MPA total body exposure,
is inconvenient, expensive and difficult to achieve as well
as influenced by MPA enterohepatic recirculation. There-
fore, there are attempts to determine C0 in clinical practice,
although poor correlation between MPA C0 and AUC0–12 is
observed (Budde et al. 2007b; Durlik and Rowin´ski 2012).
The aim of the study was to investigate the pharma-
cokinetics of EC-MPS metabolites (MPA, fMPA and
MPAG) and the clinical condition of kidney transplant
recipients receiving concomitantly Tac and steroids in the
first year after transplantation.
2 Patients and methods
2.1 Patients
The study included 18 patients aged 34–72 years within
1 year after transplantation (14–307 days), receiving EC-
MPS orally at a daily dose of 1,440 mg (720 mg bid) in
combination with Tac and steroids (prednisolone). The
inclusion criteria were Tac treatment (Advagraf or Prograf)
and appropriate EC-MPS dosage (the same dose twice a
day). The exclusion criteria were CsA treatment, EC-MPS
given in different dosage schedule than twice a day or at
two different doses. The patients’ demographics and clin-
ical characteristics are presented in Table 1. The protocol
biopsies were not performed. Biopsies were taken in the
case of acute rejection suspicion based on clinical symp-
toms. After receiving the biopsy result (within 24 h)
definitive diagnosis was made. None of the patients showed
biopsy-proven acute rejection.
The study was approved by the Bioethical Committee at
Poznan University of Medical Sciences and is in accor-
dance with the Helsinki Declaration of 1975. Informed
consent was obtained from the patients prior to initiating
the study.
2.2 MPA, fMPA and MPAG determination
Blood samples were collected into EDTA tubes before the
morning dose of EC-MPS (C0), and subsequently at 30 min
(C0.5), 1 h (C1), 2 h (C2), 3 h (C3), 4 h (C4), 6 h (C6), 9 h
(C9) and 12 h (C12) after EC-MPS administration. All
patients were at the steady state on the day of blood
collection.
MPA and MPAG plasma concentrations were deter-
mined using the validated HPLC method described else-
where (Elbarbry and Shoker 2007; Chrzanowska et al.
2011) with minor modification. 200 lL of plasma was
mixed with 100 lL of MPA and MPAG standard solutions
for the calibration curve or substituted for 100 lL of
methanol in the case of patients’ plasma samples. Subse-
quently, 200 lL of phenytoin (internal standard) dissolved
in 0.1 mol/L orthophosphoric acid in acetonitrile was
added.
Free MPA (fMPA) was analyzed according to the
method described elsewhere (Chen et al. 2010) in all
plasma samples. The analytical column used for fMPA
determination was Zorbax Eclipse XDB C18
(150 mm 9 4.6 mm, 5 lm, Agilent Inc., USA).
2.3 Pharmacokinetic calculations
The following pharmacokinetic parameters for MPA,
fMPA and MPAG were calculated: C0, Cmax, tmax and AUC
from 0 to 4 h (AUC0–4) and from 0 to 12 h (AUC0–12)
Table 1 Demographic and clinical data of 18 renal transplant
recipients
Parameter Median Min–Max
Gender Male: 10; female: 8
Age (years) 55 34–72
Post-transplant period (days) 34 14–307
Tacrolimus dose (mg/day) 7 5–16
Creatinine concentration (mg/dL) 2.1 1.1–7.3
Creatinine clearance (mL/min/1.73 m2) 31.9 7.3–83.5
Platelets count (10-9/L) 209 67–380
White blood cells count (10-9/L) 7.9 3.2–17.3
Hemoglobin concentration (g/dL) 11.2 9.1–16.7
Alanine aminotransferase (U/L) 30 7–177
Aspartate aminotransferase (U/L) 19 9–43
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using the linear trapezoidal rule. The creatinine clearance
(CLcr) was estimated using Chronic Kidney Disease Epi-
demiology Collaboration equation (Levey et al. 2009). For
fMPA, the fraction of fMPA (%) was also calculated.
2.4 Statistical analysis
All statistical tests were performed using Statistica soft-
ware version 10.0 (StatSoft, Cracow, Poland). Normality
was determined by the Shapiro–Wilk test. The correlations
of data were tested using Pearson or Spearman correlation
analysis for the normally and non-normally distributed
data, respectively. A p value lower than 0.05 was consid-
ered significant. The results are presented as
mean ± standard deviation (SD). Coefficient of variation
(CV) was used to express variability of pharmacokinetic
parameters.
3 Results
3.1 Pharmacokinetic parameters of MPA, fMPA
and MPAG
Individual plasma concentrations of MPA, fMPA and
MPAG versus time for all patients included in the study are
shown on Fig. 1.
The calculated MPA, fMPA and MPAG pharmacoki-
netic parameters are presented in Table 2. Plasma con-
centrations of MPA, fMPA and MPAG as well as the
pharmacokinetic parameters of EC-MPS metabolites were
highly variable. Median MPA C0 was 3.1 lg/mL and the
highest MPA C0 in our study was 10.6 lg/mL. 50 % of
patients reached MPA AUC0–12 therapeutic range of
30–60 lg h/mL, whereas for the rest of the patients MPA
AUC0–12 was[60 lg h/mL. For 33 % MPA AUC0–12
value was within 40–60 lg h/mL.
The average percentage of fMPA fraction was
0.90 ± 0.76 % (median 0.77 %, range 0.28–7.29 %). The
median fMPA AUC0–12 was 0.449 lg h/mL. In 11 of 18
patients (61 %) fMPA AUC0–12 was[0.4 lg h/mL.
Most of the MPA, fMPA and all MPAG concentrations
correlated significantly with MPA, fMPA and MPAG
AUC0–12 and AUC0–4 as presented in Table 3. MPA C2 did
not correlate with MPA AUC0–12. Moreover, MPA C0 and
C0.5 did not correlate with MPA AUC0–4.
The median MPAG AUC0–12 was about 20-fold higher
than MPA AUC0–12 values.
In our study, there were no differences in MPA, fMPA
and MPAG pharmacokinetic parameters between patients
\30 days after the transplantation and patients [30 days
after the transplantation (data not shown).
3.2 Kidney function
The influence of kidney function on pharmacokinetic
parameters was analyzed regarding creatinine clearance
(CLcr) and creatinine concentration (Ccr). MPAG pharma-
cokinetic parameters (AUC0–4, AUC0–12, C0, Cmax) corre-
lated negatively with CLcr and positively with Ccr, whereas
none of the MPA pharmacokinetic parameters correlated
with CLcr and Ccr. AUC0–12 of fMPA correlated positively
with Ccr (Table 4).
3.3 Patient characteristics and complete blood count
parameters
None of the MPA, fMPA and MPAG pharmacokinetic
parameters correlated either with patient characteristics
(age, weight, post-transplant period and Tac dose; data not
shown) or with the results of the complete blood count
tests [white blood cell (WBC) and platelet (PLT) count,
hemoglobin (Hb) concentration; data not shown] with the
exceptions of the negative correlations between Hb con-
centration and MPA C0 (r = -0.475; p = 0.046) as well
as fMPA C0 (r = -0.540, p = 0.021).
4 Discussion
The aim of our study was to calculate the pharmacokinetic
parameters of MPA, fMPA and MPAG in renal transplant
recipients treated with EC-MPS, Tac and steroids within
1 year after the transplantation and to compare the results
with the literature data concerning EC-MPS administration
with either CsA or Tac. We also assessed the influence of
kidney function as well as other clinical factors on EC-
MPS metabolites pharmacokinetics. Additionally, MPA
and MPAG concentrations were correlated with MPA and
MPAG AUC0–12 as well as with the abbreviated AUC0–4.
The results may contribute to assess limited sampling
strategy (LSS), which would be more convenient for pa-
tients and may be useful for individualizing drug dosage
(Pawinski et al. 2002).
Consistent with the literature data (Budde et al. 2007b;
Hummel et al. 2007; Shah et al. 2011; Fleming et al. 2011),
plasma concentrations of MPA, fMPA and MPAG in our
study were found to range widely. According to the CV
values, the pharmacokinetic parameters of EC-MPS
metabolites were highly variable as well.
Our results are in accordance with the literature data
concerning the influence of calcineurin inhibitors on MPA
and MPAG pharmacokinetics. In patients included in our
study, MPA pharmacokinetic parameters were higher in
comparison to patients receiving EC-MPS in combination
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Fig. 1 Individual plasma
concentrations of mycophenolic
acid (MPA; a), free MPA
(fMPA; b) and mycophenolate
glucuronide (MPAG; c) versus
time in 18 kidney transplant
recipients treated with enteric-
coated mycophenolate sodium
(EC-MPS) and tacrolimus (Tac)
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with CsA (Budde et al. 2007b; Stracke et al. 2012) and
comparable to the literature data in Chinese patients
receiving EC-MPS and Tac with the exception of shorter
MPA tmax in our study (5.0 vs. 2.0 h) (Li et al. 2013). MPA
tmax in our study was comparable, however, to most of the
literature data (1.5–3.5 h) (Budde et al. 2007a; Shah et al.
2011; Tett et al. 2011; Stracke et al. 2012). All MPAG
pharmacokinetic parameters in our study were lower than
those in patients receiving EC-MPS with CsA (Stracke
et al. 2012). The median MPAG AUC0–12 was about
20-fold higher than MPA AUC0–12 values and the result
was lower than those in patients receiving EC-MPS in
combination with CsA (52-fold higher for MPAG) (Stracke
et al. 2012).
Table 2 The pharmacokinetic parameters of MPA, fMPA and MPAG in renal transplant recipients
Parameter MPA fMPA MPAG
Mean ± SD Median CV (%) Mean ± SD Median CV (%) Mean ± SD Median CV (%)
C0 (lg/mL) 4.2 ± 3.0 3.1 71.6 0.030 ± 0.025 0.022 83.4 117.3 ± 78.2 96.9 66.7
Cmax (lg/mL) 18.1 ± 7.5 16.1 41.3 0.174 ± 0.107 0.156 61.3 163.8 ± 76.8 148.1 46.9
tmax (h) 2.0 ± 0.6 2.0 29.7 2.0 ± 1.0 2.0 51.4 3.4 ± 1.6 3.0 48.7
AUC0–12 (lg h/mL) 67.4 ± 30.6 61.4 45.4 0.487 ± 0.294 0.449 60.3 1,547.5 ± 844.7 1,393.2 54.6
AUC0–4 (lg h/mL) 34.2 ± 14.3 28.2 41.8 0.450 ± 0.285 0.410 63.4 577.2 ± 417.7 472.6 72.4
fMPA fraction (%) – – – 0.90 ± 0.76 0.77 84.1 – – –
Table 3 Correlations between MPA, fMPA and MPAG concentrations and respective AUC0–4 and AUC0–12 in renal transplant recipients
C (lg/mL) MPA fMPA MPAG
AUC0–12 (lg h/mL) AUC0–4 (lg h/mL) AUC0–12 (lg h/mL) AUC0–4 (lg h/mL) AUC0–12 (lg h/mL) AUC0–4 (lg h/mL)
r p r p r p r p r p r p
C0 0.560 0.016 0.404 0.097 0.732 0.001 0.752 \0.001 0.955 \0.001 0.950 \0.001
C0.5 0.564 0.015 0.443 0.066 0.709 0.001 0.728 0.001 0.955 \0.001 0.955 \0.001
C1 0.595 0.009 0.618 0.006 0.804 \0.001 0.796 \0.001 0.971 \0.001 0.977 \0.001
C2 0.335 0.174 0.550 0.018 0.525 0.025 0.511 0.030 0.833 \0.001 0.884 \0.001
C3 0.858 \0.001 0.769 \0.001 0.503 0.034 0.496 0.036 0.942 \0.001 0.957 \0.001
C4 0.759 \0.001 0.589 0.010 0.457 0.056 0.437 0.070 0.975 \0.001 0.953 \0.001
C6 0.666 0.003 – – 0.313 0.206 – – 0.948 \0.001 – –
C9 0.639 0.004 – – 0.847 \0.001 – – 0.959 \0.001 – –
C12 0.666 0.003 – – 0.612 0.007 – – 0.948 \0.001 – –
Cmax 0.517 0.028 0.781 \0.001 0.872 \0.001 0.874 \0.001 0.959 \0.001 0.953 \0.001
Table 4 Correlations between
MPA, fMPA and MPAG
pharmacokinetic parameters and
renal function in renal transplant
recipients
* Pearson correlation analysis
MPA fMPA MPAG
r p r p r p
Creatinine clearance (mL/min)
AUC0–4 (lg h/mL) -0.024 0.926 -0.373 0.128 -0.690 0.002
AUC0–12 (lg h/mL) 0.063 0.804 -0.414 0.088 -0.657 0.003
C0 (lg/mL) -0.191 0.448 -0.356 0.147 -0.697 0.001
Cmax (lg/mL) 0.168* 0.505 -0.207* 0.409 -0.630* 0.005
Creatinine concentration (mg/dL)
AUC0–4 (lg h/mL) 0.046 0.855 0.467 0.051 0.676 0.002
AUC0–12 (lg h/mL) -0.013 0.958 0.494 0.037 0.634 0.005
C0 (lg/mL) 0.276 0.268 0.436 0.071 0.654 0.003
Cmax (lg/mL) -0.031 0.903 0.372 0.129 0.605 0.008
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The target recommended MPA C0 value is C1.3
and C1.9 lg/mL for renal transplant recipients receiving
MMF with CsA and MMF with Tac, respectively (van
Gelder et al. 2006). Although it has not been thoroughly
investigated, the target MPA C0 for MMF may not be
applicable for EC-MPS due to two reasons. First, the
enteric-coating of EC-MPS delays the occurrence of Cmax
and second, after EC-MPS administration higher and more
variable MPA C0 with overall MPA exposure similar to
that observed after MMF administration are observed
(Budde et al. 2007a, b; Stracke et al. 2012). For MMF and
Tac, MPA C0[3 lg/mL may be related to more common
adverse effects (Borrows et al. 2006); however, in our
study, 9 of 18 patients (50 %) had MPA C0[3 lg/mL and
no significant adverse effects were observed. None of the
patients in our study reached MPA C0 15 lg/mL, which
could be related to very prolonged release of MPA from the
evening EC-MPS dose. It is proved that MPA and MPAG
exposures increased from week 2 to week 12 post-trans-
plant after prolonged EC-MPS and CsA co-administration
(Hummel et al. 2007). In our study, however, probably due
to a small number of patients, none of the MPA or MPAG
pharmacokinetic parameters correlated with the post-
transplant period and we did not observe any differences in
the pharmacokinetics between patients who were within
30 days [the early post-transplant period (Stracke et al.
2012)], and those who were more than 30 days after the
transplantation. The highest and the lowest MPAG C0 were
observed 22 and 14 days after the transplantation, respec-
tively. The only patient who was[6 months after the
transplantation had one of the lowest MPA and MPAG C0
values.
The target MPA AUC value, recommended for suffi-
cient immunosuppression in renal transplant recipients
receiving MMF and CsA, especially in the early post-
transplant period, is 30–60 lg h/mL (van Gelder et al.
2006; Sanford and Keating 2008) or 40–60 lg h/mL for
EC-MPS and CsA therapy (Glander et al. 2010; Stracke
et al. 2012). MPA AUC0–12 therapeutic range of
30–60 lg h/mL was reached in 9 of 18 patients (50 %)
included in our study. The AUC0–12 values in the remain-
ing 50 % of the patients exceeded the upper limit of the
therapeutic range ([60 lg h/mL). Although the toxic range
for MPA AUC has not been established, AUC[60 lg h/
mL may be related to the increased incidence of the
adverse events such as leucopenia, thrombocytopenia and
gastrointestinal disorders. Some authors also observed high
MPA AUC0–12 after EC-MPS and Tac therapy without
greater incidence of the adverse effects (Shah et al. 2011;
Sa´nchez Fructuoso et al. 2012). Sumethkul et al. (2005)
reported high MPA AUC exposure ([60 lg h/mL) also
after EC-MPS and CsA therapy. The percentage of patients
(33 %), who reached MPA AUC0–12 therapeutic range of
40–60 lg h/mL in our study, was slightly higher than in
the Stracke et al. (25 %) study. Apart from the kind of
calcineurin inhibitor administered, higher MPA AUC may
be due to a different MPA determination method (enzyme-
multiplied immunoassay) (Sa´nchez Fructuoso et al. 2012).
The data concerning the relationship between MPA
exposure and the incidence of acute rejection are limited in
renal transplant recipients treated with EC-MPS (Le Meur
et al. 2011). According to the literature (Budde et al. 2010),
patients with biopsy-proven acute rejection showed lower
MPA AUC0–12 (28 lg h/mL) in comparison to the rejec-
tion-free patients (MPA AUC0–12 40 lg h/mL). In our
study, we did not observe any acute rejection, probably
because MPA AUC0–12 was[30 lg h/mL in all patients.
In our study, MPA C0 correlation with AUC0–12 was
weaker than that in the Budde et al. (2007b) study and
stronger than that in the Stracke et al. (2012) study. Poor
correlations between C0 and total MPA AUC, which may
be even weaker for EC-MPS than for MMF, indicate that
MPA C0 does not reflect systemic exposure to MPA
regardless of the kind of calcineurin inhibitor (CsA or Tac)
co-administered (Pawinski et al. 2002; Budde et al. 2007b;
Neumann et al. 2008; de Winter et al. 2008; Sa´nchez
Fructuoso et al. 2012; Li et al. 2013). In our study, all MPA
concentrations (except for C2) correlated significantly with
MPA AUC0–12 as well as with MPA AUC0–4. The most
significant correlations were observed for MPA C3 and C4
similar to or even stronger than those in the literature
(Sa´nchez Fructuoso et al. 2012; Stracke et al. 2012).
However, in the case of EC-MPS some authors suggest that
the estimation of MPA AUC0–12 based on the plasma
concentrations drawn within 2 or 3 h after dosing is likely
to provide conflicting results due to the variability in MPA
tmax (Tett et al. 2011). In patients included in our study,
MPA C12 correlated significantly with AUC0–12 stronger
than in the Stracke et al. (2012) study, whereas in Chinese
patients treated with EC-MPS and Tac, MPA C7 predicted
MPA AUC the best (Li et al. 2013).
In therapeutic monitoring, MPA Cmax should preferably
rather not be used due to its weaker correlation with MPA
AUC0–12 and great tmax variability (Budde et al. 2007a;
Shah et al. 2011; Tett et al. 2011; Stracke et al. 2012). This
is confirmed in our study as the correlation between MPA
Cmax and MPA AUC0–12 was the second weakest.
All MPAG concentrations correlated significantly with
MPAG AUC0–12 and AUC0–4. The best correlations were
seen between C1 and C4 and the weakest in C2. According
to the literature data, patients treated with EC-MPS in
combination with CsA, C0, C2, C12 and Cmax correlated
well with the MPAG AUC0–12 (Stracke et al. 2012).
Additionally, we observed significant correlations
between most of the fMPA concentrations and fMPA
AUC0–12 and AUC0–4. This finding may contribute to
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therapeutic monitoring as the determination method of
fMPA is fast and easy (Chen et al. 2010). Median fMPA
AUC0–12 presented in our study was similar to the literature
data (0.48 lg h/mL) but median fMPA fraction was lower
(0.77 vs. 1.65 %) (Stracke et al. 2012).
Higher values of MPAG pharmacokinetic parameters
observed in patients with lower CLcr and higher Ccr are
in accordance with the literature data. Some authors
observed significant negative correlations between
glomerular filtration rate and MPAG and fMPA AUC0–12
and lack of correlation for MPA AUC0–12 (Stracke et al.
2012). According to the literature data, high values of
MPAG pharmacokinetic parameters result from MPAG
accumulation in patients with impaired renal function
(Behrend and Braun 2005). We also observed higher
fMPA C0 in patients with lower CLcr. Our results showed
that in one patient with very high MPA and MPAG
concentrations, Ccr amounted to 7.3 mg/dL and exceeded
the reference range by about fivefold. The CLcr value for
this patient (7.3 mL/min 1.73 m2) indicated end-stage
renal insufficiency.
We also analyzed the influence of complete blood count
parameters, such as WBC and PLT counts, Hb concentra-
tion, as well as other factors (patients’ age, Tac dose) on
MPA, fMPA and MPAG pharmacokinetic parameters. We
found one study, concerning patients receiving EC-MPS
and CsA, where neither MPA nor MPAG pharmacokinetics
correlated with WBC and PLT counts or with Hb and
albumin concentrations (Stracke et al. 2012). In our study,
no significant correlations, except for lower Hb concen-
trations in patients with higher MPA C0 and fMPA C0,
were observed. Nevertheless, these correlations indicate
the necessity of MPA C0 monitoring during EC-MPS and
Tac treatment as too high MPA C0 may contribute to
anemia onset in these patients.
5 Conclusion
The significant correlations between MPA C3 as well as
MPA C4 and MPA AUC0–4 and MPA AUC0–12 may be of
importance in further studies including larger number of
patients in regard to establishing LSS. Similarly as for
MMF therapy, in EC-MPS treated patients MPAG con-
centration is related to renal function as MPAG pharma-
cokinetics were higher in patients with renal impairment.
In patients treated with EC-MPS and Tac, monitoring MPA
C0 may be important, as too high MPA C0 may contribute
to anemia onset. However, it should be emphasized that
there are some limitations in this study, e.g. the lack of a
control group, the cross-sectional design and the small
number of patients. This work may serve as a starting point
for further and multicenter studies.
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